Exact raises $103M in follow-on

Exact Sciences Corp. (NASDAQ:EXAS) raised $103 million through the sale of 4 million shares at $25.75 in a follow-on underwritten by Jefferies and Baird.

FDA approved Exact's Cologuard in August. The non-invasive DNA screening test for colorectal cancer uses a multiplexed quantitative Invader assay for the simultaneous detection of methylated and unmethylated sequences in the promoter region of the vimentin (VIM) gene. ...